Post-Traumatic Stress Disorder (PTSD) Clinical Trials

Find Post-Traumatic Stress Disorder (PTSD) Clinical Trials Near You

Transcranial Magnetic Stimulation as Treatment for Persistent PTSD in Texas Youth

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to test whether transcranial magnetic stimulation, or TMS, is an acceptable and helpful treatment for ongoing symptoms of posttraumatic stress syndrome disorder (PTSD) in 12-20 year olds. Ongoing PTSD refers to symptoms that continue after completing trauma-focused psychotherapy. About 1 in 4 patients need additional help to overcome PTSD after completing psychotherapy. Currently, scientists do not know the best way to help adolescents with persistent PTSD, and this study will test TMS as a possible treatment, and hopefully lead to future studies including more people.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 20
Healthy Volunteers: f
View:

• Males and females; Age 12-20

• Have previously completed at least 9 sessions of trauma-focused therapy in our clinical trial or in the community

• Have current self-reported symptom score of 20 or greater on the UCLA PTSD Reaction index

• Willing to attend 10 TMS treatment sessions within a 30-day period

• Fluent in English

Locations
United States
Texas
UT Health Department of Psychiatry
RECRUITING
San Antonio
Contact Information
Primary
Amy S Garrett, PhD
GarrettAS@uthscsa.edu
210-567-8189
Time Frame
Start Date: 2026-05-09
Estimated Completion Date: 2027-08-31
Participants
Target number of participants: 20
Treatments
Experimental: TMS treatment group
Each treatment visit will take about 1.5 hours. Participants will receive up to 4 TMS treatment sessions during the visit, with each session lasting about 10-minutes. After the TMS sessions, there will be a brief visit with a psychotherapist.
Related Therapeutic Areas
Sponsors
Collaborators: Texas Child Mental Health Care Consortium: TCMHCC
Leads: The University of Texas Health Science Center at San Antonio

This content was sourced from clinicaltrials.gov